• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      ASH 2021 - The 63rd American Society of Haematology Annual Meeting and Exposition

      About the latest data for VENCLYXTO® in Acute Myloid Leukaemia (AML)

      To receive the latest AbbVie information on upcoming congresses


      On demand: Access content from ASH 2021

      Dr Steve Knapper and Dr Richard Dillon

      Insights from ASH 2021:
      Acute Myeloid Leukaemia

      Dr Steve Knapper and Dr Richard Dillon review the findings of VIALE-A trial study

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCAML-220028. Date of Preparation: April 2022.